Evidence map›Paper›PMID 32392708›Full record

ArticleCancers2020

The Extracellular Matrix Influences Ovarian Carcinoma Cells' Sensitivity to Cisplatinum: A First Step towards Personalized Medicine.

Andrea Balduit, Chiara Agostinis, Alessandro Mangogna, Veronica Maggi, Gabriella Zito, Federico Romano, Andrea Romano, Rita Ceccherini, Gabriele Grassi, Serena Bonin and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Andrea BalduitDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.ORCID 0000-0001-5902-3205
Chiara AgostinisInstitute for Maternal and Child Health, IRCCS Burlo Garofolo, 34134 Trieste, Italy.ORCID 0000-0002-8315-2258
Alessandro MangognaDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.ORCID 0000-0001-7910-1274
Veronica MaggiDepartment of Medical, Surgical and Health Science, University of Trieste, 34129 Trieste, Italy.
Gabriella ZitoInstitute for Maternal and Child Health, IRCCS Burlo Garofolo, 34134 Trieste, Italy.
Federico RomanoInstitute for Maternal and Child Health, IRCCS Burlo Garofolo, 34134 Trieste, Italy.ORCID 0000-0003-2157-8330
Andrea RomanoDepartment of Medical, Surgical and Health Science, University of Trieste, 34129 Trieste, Italy.
Rita CeccheriniCentro Sociale Oncologico, OSARF, Azienda Sanitaria Universitaria Giuliano Isontina, 34127 Trieste, Italy.
Gabriele GrassiDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Serena BoninDepartment of Medical, Surgical and Health Science, University of Trieste, 34129 Trieste, Italy.ORCID 0000-0002-7349-0296
Deborah BonazzaDepartment of Medical, Surgical and Health Science, University of Trieste, 34129 Trieste, Italy.
Fabrizio ZanconatiDepartment of Medical, Surgical and Health Science, University of Trieste, 34129 Trieste, Italy.
Giuseppe RicciInstitute for Maternal and Child Health, IRCCS Burlo Garofolo, 34134 Trieste, Italy.ORCID 0000-0002-8031-1102
Roberta BullaDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.ORCID 0000-0003-1737-5776
University of Trieste · ITIRCCS Materno Infantile Burlo Garofolo · ITAzienda Sanitaria Universitaria Integrata di Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of personalized therapies for ovarian carcinoma patients is still hampered by several limitations, mainly the difficulty of predicting patients' responses to chemotherapy in tumor cells isolated from peritoneal fluids. The main reason for the low predictive power of in vitro assays is related to the modification of the cancer cells' phenotype induced by the culture conditions, which results in changes to the activation state and drug sensitivity of tumor cells compared to their in vivo properties. We have defined the optimal culture conditions to set up a prognostic test to predict high-grade serous ovarian carcinoma (HGSOC) patients' responses to platinum chemotherapy. We evaluated the effects of hyaluronic acid (HA) and fibronectin matrices and the contribution of freezing/thawing processes to the cell response to platinum-based treatment, collecting spheroids from the ascitic fluids of 13 patients with stage II or III HGSOC. Our findings indicated that an efficient model used to generate predictive data for in vivo sensitivity to platinum is culturing fresh spheroids on HA, avoiding the use of previously frozen primary tumor cells. The establishment of this easy, reproducible and standardized testing method can significantly contribute to an improvement in therapeutic effectiveness, thus bringing the prospect of personalized therapy closer for ovarian carcinoma patients.

Indexed as

chemoresistancefibronectinHGSOChyaluronic acidovarian cancerpersonalized medicinespheroids

Identifiers

PMID32392708
PMCPMC7281165
OpenAlexW3022813327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.